| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, Par Value $0.001 |
| (b) | Name of Issuer:
SPERO THERAPEUTICS, INC. |
| (c) | Address of Issuer's Principal Executive Offices:
675 MASSACHUSETTS AVENUE, 14TH FLOOR, Cambridge,
MASSACHUSETTS
, 02139. |
Item 1 Comment:
This Amendment No. 9 to Schedule 13D (this "Statement") amends and supplements the statement on Schedule 13D originally filed on November 16, 2017 and amended on July 17, 2018, September 19, 2018, February 14, 2020, June 4, 2020, December 7, 2020, September 16, 2021, November 14, 2022 and January 20, 2023 (the "Schedule 13D") with respect to the shares of common stock, par value $0.001 per share (the "Common Stock"), of Spero Therapeutics, Inc., a Delaware corporation (the "Issuer"). The Reporting Person is filing this amendment to disclose its new percentage beneficial ownership in the Issuer, which has been decreased as a result of an increase in the outstanding shares of Common Stock of the Issuer. The Issuer's principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. |
| Item 2. | Identity and Background |
|
| (a) | The response set forth in Item 2 of Schedule 13D is hereby amended in its entirety and replaced with the following:
This Statement is being filed on behalf of GSK, a public limited company incorporated under the laws of England and Wales. GSK and its subsidiaries constitute a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. |
| (b) | GSK's principal offices located at 79 New Oxford Street, London, WC1A 1DG, United Kingdom. |
| (c) | Set forth in Schedule 1 to this Statement are the name, business address and present principal occupation or employment and citizenship of each executive officer and director of GSK. The Common Stock are held directly by GSK Equity Investments, Limited, and Glaxo Group Limited, each of which is an indirect, wholly-owned subsidiary of GSK plc. |
| (d) | During the last five years prior to the date hereof, neither GSK nor, to the best knowledge of GSK, any of the other persons with respect to whom information is given in response to this Item 2 has been convicted in a criminal proceeding or been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:
(a), (b) The information contained in rows 7, 8, 9, 10, 11, and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5. |
| Item 7. | Material to be Filed as Exhibits. |
| | Schedule 1 - Item 2(c) |
